Early goal-directed therapy in the management of severe sepsis or septic shock in adults: a meta-analysis of randomized controlled trials

Ling Zhang1, Guijun Zhu2, Li Han3 and Ping Fu4*

Abstract

Background: The Surviving Sepsis Campaign guidelines have proposed early goal-directed therapy (EGDT) as a key strategy to decrease mortality among patients with severe sepsis or septic shock. However, its effectiveness is uncertain.

Methods: We searched for relevant studies in Medline, Embase, the Cochrane Library, Google Scholar, and a Chinese database (SinoMed), as well as relevant references from January 1966 to October 2014. We performed a systematic review and meta-analysis of all eligible randomized controlled trials (RCTs) of EGDT for patients with severe sepsis or septic shock. The primary outcome was mortality; secondary outcomes were length of ICU and in-hospital stay, mechanical ventilation support, vasopressor and inotropic agents support, fluid administration, and red cell transfusion. We pooled relative risks (RRs) or weighted mean differences (MDs) with 95% confidence intervals (95% CI) using Review Manager 5.2.

Results: We included 10 RCTs from 2001 to 2014 involving 4,157 patients. Pooled analyses of all studies showed no significant difference in mortality between the EGDT and the control group (RR 0.91, 95% CI: 0.79 to 1.04, \(P = 0.17\)), with substantial heterogeneity (\(\chi^2 = 23.65, I^2 = 58\%\)). In the subgroup analysis, standard EGDT, but not modified EGDT, was associated with lower mortality rate in comparison with the usual care group (RR 0.84, 95% CI: 0.72 to 0.98, \(P = 0.03\)). However, EGDT was associated with a higher mortality rate in comparison with the early lactate clearance group (RR 1.52, 95% CI: 1.06 to 2.18, \(P = 0.02\)). In the first 6 h, compared with usual care, patients in EGDT received more inotropic agents (\(P = 0.04\)), fluid administration (\(P = 0.05\)), and red cell transfusion (\(P < 0.01\)). There were no significant differences in length of ICU stay (\(P = 0.73\)) or in-hospital stay (\(P = 0.57\)), ventilation rate (\(P = 0.53\)), and vasopressor support (\(P = 0.63\)).

Conclusions: EGDT was not associated with a survival benefit among patients with severe sepsis or septic shock. Instead, EGDT was associated with a higher mortality rate in comparison to the early lactate clearance group. Further high-quality RCTs comparing EGDT with early lactate clearance are desirable.

Keywords: EGDT, Early goal-directed, Resuscitation, Sepsis, Meta-analysis

Background

Severe sepsis and septic shock are common complications of patients with critical illness, with an annual incidence of up to 300 cases per 100,000 people in the United States [1]. Despite efforts to improve its management, sepsis remains the 10th leading cause of death in the United States, with an associated mortality of 20% to 50% [1-3]. In 2001, Rivers et al. first reported that a specific 6-h protocol of early goal-directed therapy (EGDT) significantly reduced the mortality rate of patients with severe sepsis and septic shock presenting to the emergency department, as compared with the usual therapy [4]. EGDT was subsequently incorporated into the 6-h resuscitation bundle of the Surviving Sepsis Campaign guidelines [5-7], and many studies showed a survival benefit with EGDT or a sepsis bundle including EGDT [8-12]. However, in 2014, two multicenter randomized controlled trials (RCTs) showed that EGDT was not...
associated with a survival benefit in comparison with usual care [13,14]. A recent cohort study showed that EGDT might increase the risk of fluid overload and mortality [15]. Thus, we sought to systematically review the current literature and to analyze all studies implementing EGDT for the management of patients with severe sepsis or septic shock.

Materials and methods

We performed this systematic review using the guidelines proposed by the Cochrane Collaboration in the Cochrane Handbook for Systematic Reviews of Interventions [16]. There was no registered protocol.

Study selection criteria

Participants

This review focused on patients with severe sepsis or septic shock who received EGDT or a sepsis bundle including EGDT.

Interventions

For the purpose of the review, we use the term “EGDT” to describe standard EGDT, modified EGDT, or a sepsis bundle based on standard EGDT, with details presented in Table 1. Standard EGDT was described as a 6-h protocol resuscitation conforming to specific therapeutic targets of central venous pressure (CVP) between 8 and 12 mm Hg, mean arterial pressure (MAP) between 65 and 90 mm Hg, urine output 0.5 ml/kg/h or more, and continuous monitoring to keep central venous oxygen saturation (ScvO2) at 70% or above [4]. We defined modified EGDT as a similar or simplified 6-h protocol based on standard EGDT [4]. The intervention of the control group was usual care or other strategies described in original studies.

Types of outcome measures

The primary outcomes were mortality among patients with severe sepsis or septic shock. Length of ICU and in-hospital stay, mechanical ventilation support, vasopressor and inotropic agents support, fluid administration and red cell transfusion rate in the first 6 h were also analyzed.

Types of studies

We included all RCTs comparing EGDT with usual care or other strategies for patients with severe sepsis or septic shock. We excluded non-randomized studies, studies published in abstracts, reviews, commentaries, and editorials.

Search methods for identification of studies

Study selection

We used the Cochrane risk of bias tool [17] to undertake, and the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement methodology [18] to report, a systematic review and meta-analysis of RCTs. Two independent reviewers (LZ and GZ) conducted a search in PubMed, Embase, the Cochrane Library, Google Scholar, a Chinese database (SinoMed), and major critical care medicine journals. Trials were considered without language or date restriction. We performed the last updated search on 5 October 2014. The following text words and corresponding heading terms were used as search terms: “sepsis or septic shock” and “EGDT or early goal directed or goal directed or goal targeted or sepsis bundle or hemodynamic optimization or protocol or program or procedure”. The exact search strategy was provided in Appendix 1. Related articles and reference lists were manually searched to avoid omissions. After title screening, we evaluated abstracts for relevance and identified them as included, excluded, or requiring further assessment. At this stage, if a paper required further assessment, we contacted the study lead investigator by e-mail and/or telephone with a request for further information.

Data extraction

The inclusion criteria were as follows: (a) sepsis patients with hypotension (systolic blood pressure of less than 90 mm Hg or a mean arterial pressure of less than 65 mm Hg) or hypoperfusion (blood lactate level of 4.0 mmol per liter or more); and (b) studies comparing EGDT with usual care or other intervention, and (c) sufficient data available to calculate a relative risk (RR) or mean difference (MD) with 95% confidence interval (95% CI). The following exclusion criteria were used: (a) EGDT was performed in all patients or studies of compliance with EGDT; and (b) EGDT not based on published protocol [4]; and (c) pediatric patients; and (d) nonhuman studies. For studies with the same or overlapping data by the same authors, the most suitable studies with the largest number of cases or latest publication dates were selected.

Two investigators (LZ and GZ) assessed each trial independently and recorded eligibility, quality, and outcomes. Disagreements regarding eligibility arose with 7% of the articles (κ = 0.87), which were resolved by a third party through consensus. A third investigator (FP) provided arbitration in case of disagreement. We extracted the following study features: first author, publication year, country, number of participants, protocol of EGDT, mortality, length of ICU and in-hospital stay, ventilation rate, vasopressor support, inotropic agents support, and
| Study                  | EGDT group                                                                 | Control group                  | Survival benefit                                      |
|-----------------------|-----------------------------------------------------------------------------|--------------------------------|-----------------------------------------------------|
| **Standard EGDT versus usual care** |                                                                             |                                |                                                     |
| ARISE 2014 [13]       | ScvO$_2$ ≥ 70%; CVP ≥ 8-12 mm Hg; MAP ≥ 65 mm Hg; UO ≥ 0.5 ml/kg/h           | Usual care                     | No: 28d/90d/ICU/in-hospital mortality                |
| Jing 2010 [8]         | ScvO$_2$ ≥ 70%; CVP ≥ 8-12 mm Hg; SBP > 100 mm Hg; MAP ≥ 65 mm Hg; UO ≥ 0.5 ml/kg/h | CVP ≥ 8-12 mm Hg               | Yes: 28d/ICU mortality                                |
| ProCESS 2014 [14]     | ScvO$_2$ ≥ 70%; CVP ≥ 8-12 mm Hg; MAP ≥ 65 mm Hg; UO ≥ 0.5 ml/kg/h           | Usual care                     | No: 60d/in-hospital mortality                        |
| Rivers 2001 [4]       | ScvO$_2$ ≥ 70%; CVP ≥ 8-12 mm Hg; MAP ≥ 65 mm Hg; UO ≥ 0.5 ml/kg/h           | JVP > 3 cm; MAP > 65 mm Hg; Hb > 7 g/dl | Yes: 28d/60d/in-hospital mortality                |
| Wang 2006 [25]        | ScvO$_2$ ≥ 70%; CVP ≥ 8-12 mm Hg; MAP ≥ 65 mm Hg; UO ≥ 0.5 ml/kg/h           | Usual care                     | No: 7d/14d mortality                                 |
| **Modified EGDT versus usual care** |                                                                             |                                |                                                     |
| Andrews 2014 [21]     | JVP > 3 cm; MAP > 65 mm Hg; Hb > 7 g/dl                                   | Usual care                     | No: 28d/in-hospital mortality                        |
| Lin 2006 [23]         | CVP ≥ 8-12 mm Hg; MAP ≥ 65 mm Hg; UO ≥ 0.5 ml/kg/h                         | Usual care                     | Yes: ICU/in-hospital mortality                       |
| ProCESS 2014 [14]     | SBP ≥ 100 mm Hg; Hb > 7.5 g/dl                                           | Usual care                     | No: 60d/in-hospital mortality                        |
| **Standard EGDT versus lactate clearance** |                                                                             |                                |                                                     |
| Jones 2010 [22]       | ScvO$_2$ ≥ 70%; CVP ≥ 8-12 mm Hg; MAP ≥ 65 mm Hg; UO ≥ 0.5 ml/kg/h         | Lactate clearance ≥ 10%        | No: in-hospital mortality                            |
| Wang 2014 [20]        | ScvO$_2$ ≥ 70%; CVP ≥ 8-12 mm Hg; MAP ≥ 65 mm Hg; UO ≥ 0.5 ml/kg/h         | Lactate < 2 mmol/L             | No: 7d/28d mortality                                 |
| Yu 2013 [24]          | ScvO$_2$ ≥ 70%; CVP ≥ 8-12 mm Hg; MAP ≥ 65 mm Hg; UO ≥ 0.5 ml/kg/h         | Lactate clearance ≥ 10%        | No: 28d mortality                                   |

**Abbreviations:** EGDT early goal-directed therapy, SBP systolic blood pressure, JVP jugular venous pressure, MAP mean artery pressure, Hb hemoglobin, UO urine output.
parameters and laboratory results. Endpoints reported in three or more articles were extracted.

**Quantitative data synthesis**

Independently and in duplicate, reviewers assessed risk of bias using the Cochrane collaboration tool [17]. For each included study, a description, a comment, and a judgment as "high", "unclear", or "low" risk of bias were provided for each of the following domains: adequate random sequence generation; allocation sequence concealment; blinding for objective outcomes; incomplete outcome data; free of selective outcome reporting; free of other bias. Studies with high risk of bias for any one or more key domains were considered as at high risk of bias. Studies with low risk of bias for all key domains were considered as at low risk of bias. Otherwise, they were considered as unclear risk of bias.

Before the analysis, data were standardized into equivalent units. For dichotomous variables such as mortality, the rates in the experimental (EGDT) and control groups were expressed as RR and 95% CI. For continuous variables such as length of ICU stay, MD and 95% CI were calculated for each study. Heterogeneity was evaluated using the Mantel-Haenszel chi-square test and the I^2 statistic to assess the degree of inter-study variation. When statistically significant heterogeneity was detected with a P value less than 0.10, a pooled analysis of each study was performed in the random-effects model. Also since the chi-square Cochran Q test for heterogeneity assessment is underpowered, a P value of 0.10 should be considered as a threshold.

Publication bias was analyzed once sufficient RCTs were identified, by visual inspection of asymmetry in funnel plots as well as the Egger's test [19]. Sensitivity analysis was conducted by sequentially deleting a single study each time in an attempt to identify the potential influence of an individual study. Data analysis was performed using Review Manager 5.2 (RevMan, The Cochrane Collaboration, Oxford, United Kingdom) and STATA 12.0 (StataCorp, College Station, TX, USA).

**Results**

**Eligible studies**

The study selection process is presented in Figure 1. The literature search yielded 542 potentially relevant records. By screening the titles, we removed 232 duplicate studies. After evaluating the abstract of each, 287 studies were excluded as they did not meet the inclusion criteria. Subsequently, we carefully read the full text of each of the remaining 23 trials and excluded 13 trials: we compared different protocols of EGDT \( (n = 4) \); overlapping data \( (n = 4) \); not all sepsis patients \( (n = 2) \); pediatric study \( (n = 2) \), and no relevant data \( (n = 1) \). Finally, 10 RCTs \([4,8,13,14,20-25]\) comparing EGDT with other interventions for severe sepsis or septic shock were included. Among the included RCTs, 5 studies compared standard EGDT with usual care \([4,8,13,14,25]\), 3 compared modified EGDT (not monitoring ScvO2) with usual care \([14,21,23]\), and 3 compared standard EGDT with early lactate clearance \([20,22,24]\).

The eligible studies were conducted from 2001 to 2014 with a total number of 2,280 patients in EGDT and 1,877 in other interventions. There were 5 studies from Asia, 3 from North America, 1 from Oceania, and 1 from Africa. A variety of outcomes were recorded in these studies, including mortality (10 studies) \([4,8,13,14,20-25]\), 28-d mortality (6 studies) \([4,8,13,20,21,24]\), in-hospital mortality (6 studies) \([4,13,14,21-23]\), length of ICU stay (6 studies) \([8,14,20,22-24]\), length of in-hospital stay (4 studies) \([14,22-24]\), ventilation rate (5 studies) \([4,13,14,22,25]\), ventilation days (4 studies) \([4,8,20,23]\), vasopressor support (6 studies) \([4,13,14,21-23]\), inotropic agents support (5 studies) \([4,13,14,22,23]\), fluid administration in the first 6 h (7 studies) \([4,13,14,21,22,24,25]\), and red cell transfusion rate in the first 6 h \([4,13,14,22,24]\). The characteristics of the RCT studies fulfilling the inclusion criteria are listed in Table 2.

**Assessment of methodological quality**

The details of risk of bias are summarized in Figure 2. Seven studies were judged to be at low risk of bias, and the other three were judged to be at unclear risk of bias. Nine trials generated adequate randomized sequences and reported appropriate allocation concealment \([4,8,13,14,21-23]\). Among all RCTs, none of them were double-blinded. However, blinding of patients and clinicians was extremely difficult in these studies to evaluate a complex intervention such as EGDT protocol, and the authors judged that the primary outcome (mortality) is not likely to be influenced by lack of blinding.

**Mortality**

A total of 10 RCTs including 4,157 patients reported data on mortality. Overall mortality was 30.4%. Of the EGDT group, 29.1% of patients died compared with 32.0% in the control group. As shown in Figure 3, pooled analyses of all studies showed that there was no significant difference in mortality between the EGDT group and the control group (RR 0.91, 95% CI: 0.77 to 1.07, \( P = 0.24 \), with substantial heterogeneity (\( \chi^2 = 23.46, I^2 = 62\% \)). There was also no significant difference in 28-d mortality (RR 0.91, 95% CI: 0.69 to 1.20, \( P = 0.50 \)) or in-hospital mortality (RR 0.91, 95% CI: 0.77 to 1.09, \( P = 0.32 \) (Figure 4). In the subgroup analysis, standard EGDT (5 studies including 3,004 patients), but not modified EGDT, was associated with a lower mortality rate in comparison to the usual care group (RR 0.91, 95% CI: 0.72 to 0.98, \( P = 0.03 \) (\( I^2 = 42\% \)). However,
Figure 1 Flow chart of selection of studies.

Table 2 Baseline characteristics of selected trials of EGDT in severe sepsis or septic shock

| Study            | Country             | N     | Male (%) | Age (y) | Center | Illness severity scores | Overall risk of bias |
|------------------|---------------------|-------|----------|---------|--------|-------------------------|----------------------|
| Andrews 2014 [21]| Zambia              | 109   | 53.2     | 35.2, 34.8 | S      | APACHE II: 17.8, 17.9   | Low                  |
| ARISE 2014 [13]  | Australia/New Zealand | 1,588 | 59.8     | 62.7, 63.1 | M      | APACHE II: 15.4, 15.8   | Low                  |
| Jing 2010 [8]    | China               | 317   | 69.3     | 68.9, 67.7 | M      | APACHE II: 23.5, 21.8   | Low                  |
| Jones 2010 [22]  | USA                 | 300   | 54.3     | 59.8, 61.6 | M      | SAPS II: 44.8, 44.1     | Low                  |
| Lin 2006 [23]    | Taiwan              | 224   | 58.0     | 67.2, 68.7 | S      | APACHE III: 66.5, 64.9  | Low                  |
| ProCESS 2014 [14]| USA                 | 1,341 | 55.4     | 60, 62    | M      | APACHE II: 20.8, 20.7   | Low                  |
| Rivers 2001 [4]  | USA                 | 263   | 50.6     | 67.1, 64.4 | S      | APACHE II: 20.4, 21.4   | Low                  |
| Wang 2006 [25]   | China               | 33    | NA       | 33, 36    | S      | APACHE II: 28, 27       | Unclear              |
| Wang 2014 [20]   | China               | 57    | 70.2     | 52, 56    | S      | APACHE II: 19.7, 20.9   | Unclear              |
| Yu 2013 [24]     | China               | 50    | 74.0     | 61, 59    | S      | APACHE II: 18.2, 17.9   | Unclear              |

Abbreviations: N number of patients, y year S, single center, M multicenter, APACHE Acute Physiology and Chronic Health Evaluation, SAPS Simplified Acute Physiology Score.
EGDT (3 studies including 407 patients) was associated with a higher mortality rate in comparison to the early lactate clearance group (RR 1.52, 95% CI: 1.06 to 2.18, \( P = 0.02 \)) \( (I^2 = 0\% \) ).

Length of ICU and in-hospital stay
A total of 6 RCTs including 1,829 patients provided information on length of ICU stay. As shown in Table 3, a Z-test in a random-effects model showed no significant difference in length of ICU stay (d) with EGDT in comparison to the control group (MD -0.20 d, 95% CI: -1.31 to 0.92; \( P = 0.73 \)). There was considerable evidence of heterogeneity \( (\chi^2 = 20.23, I^2 = 75\%) \).

Mechanical ventilation support
In Table 3, there were 5 studies including 3,082 patients that provided information on mechanical ventilation rate. No significant difference in mechanical ventilation rate was found between EGDT and the control group (RR 0.96, 95% CI: 0.85 to 1.09; \( P = 0.53 \)), and there was moderate evidence of heterogeneity \( (\chi^2 = 7.07, I^2 = 43\%) \).

A total of 4 studies including 847 patients reported data on mechanical ventilation days (d) with considerable heterogeneity \( (\chi^2 = 56.77, I^2 = 95\%) \). There was no significant difference in ventilation days with EGDT in comparison to the control group (MD -0.91 d, 95% CI: -2.34 to 0.52; \( P = 0.21 \)).

Vasopressor and inotropic agents support
There were 6 RCTs including 3,828 patients that described data on vasopressor support rate, and there was substantial heterogeneity \( (\chi^2 = 16.19, I^2 = 69\%, P < 0.01) \). There was no significant difference in vasopressor support rate between EGDT and the control group (RR 1.03, 95% CI: 0.93 to 1.15; \( P = 0.58 \)) (Table 3).

Overall, 5 RCTs including 3,273 patients provided information on inotropic agents support rate. EGDT was associated with higher inotropic agents support rate in comparison to the control group (RR 2.23, 95% CI: 1.06 to 4.67; \( P = 0.03 \)). There was considerable evidence for heterogeneity \( (\chi^2 = 25.30, I^2 = 84\%) \). In a subgroup analysis, patients in EGDT received more inotropic agents in comparison to the usual care group (RR 2.37, 95% CI: 1.02 to 5.51; \( P = 0.05 \)), whereas the results between the EGDT group and the early lactate clearance group were not significant (\( P = 0.40 \)).

Fluid administration and red cell transfusion rate in first 6 h
As shown in Table 3, a total of 7 studies including 3,204 patients provided information on fluid administration (L) in the first 6 h with considerable heterogeneity \( (\chi^2 = 788.12, I^2 = 99\%) \). There was no significant difference between EGDT and the control group (MD 0.88 L, 95% CI: -1.07 to 1.93; \( P = 0.10 \)). In a subgroup analysis, EGDT was associated with more fluid administration in the first 6 h compared with the usual care group (MD 1.24 L, 95% CI: 0 to 2.48; \( P = 0.05 \)), whereas results between the EGDT group and the early lactate clearance group were not significant (\( P = 0.27 \)).
Overall mortality
1. EGDT vs. Control group

| Study or Subgroup | EGDT Total | Control Total | Weight | Risk Ratio M-H | Random 95% CI | Risk Ratio M-H | Random 95% CI |
|-------------------|------------|---------------|--------|----------------|---------------|----------------|---------------|
| Andrews 2014      | 35 49 54   | 12.9%         | 1.07   [0.83, 1.39] |
| ARISE 2014        | 147 792 796 | 14.7%         | 0.98   [0.80, 1.21] |
| Jing 2010         | 57 159 148 | 12.6%         | 0.70   [0.54, 0.91] |
| Jones 2010        | 34 150 150 | 7.4%          | 1.36   [0.86, 2.16] |
| Lin 2006          | 53 108 116 | 14.1%         | 0.69   [0.55, 0.86] |
| ProCESS 2014      | 257 820 412 | 15.9%         | 0.93   [0.78, 1.10] |
| Rivers 2001       | 50 130 133 | 12.5%         | 0.73   [0.56, 0.96] |
| Wang 2006         | 6 16 9    | 3.5%          | 0.71   [0.33, 1.54] |
| Wang 2014         | 17 31 7   | 4.0%          | 2.04   [1.00, 4.14] |
| Yu 2013           | 7 25 5    | 2.2%          | 1.40   [0.51, 3.62] |

Total (95% CI) 2280 1877 100.0% 0.91 [0.77, 1.07]

Total events 663 600

Heterogeneity: Tau² = 0.03; Chi² = 23.46, df = 9 (P = 0.005); I² = 62%
Test for overall effect: Z = 1.18 (P = 0.24)

2. Standard EGDT vs. Usual care

| Study or Subgroup | standard EGDT Total | usual care Total | Weight | Risk Ratio M-H | Random 95% CI | Risk Ratio M-H | Random 95% CI |
|-------------------|---------------------|------------------|--------|----------------|---------------|----------------|---------------|
| ARISE 2014        | 147 792 796        | 27.1%            | 0.98   [0.80, 1.21] |
| Jing 2010         | 57 159 148         | 21.0%            | 0.70   [0.54, 0.91] |
| ProCESS 2014      | 129 405 412        | 28.2%            | 0.94   [0.78, 1.15] |
| Rivers 2001       | 50 130 133         | 20.0%            | 0.73   [0.56, 0.96] |
| Wang 2006         | 6 16 9             | 3.7%             | 0.71   [0.33, 1.54] |

Total (95% CI) 1502 1506 100.0% 0.84 [0.72, 0.98]

Total events 389 444

Heterogeneity: Tau² = 0.01; Chi² = 7.05, df = 4 (P = 0.15); I² = 41%
Test for overall effect: Z = 2.17 (P = 0.03)

3. Modified EGDT vs. Usual care

| Study or Subgroup | Modified EGDT Total | Usual care Total | Weight | Risk Ratio M-H | Random 95% CI | Risk Ratio M-H | Random 95% CI |
|-------------------|---------------------|------------------|--------|----------------|---------------|----------------|---------------|
| Andrews 2014      | 35 49 54           | 30.7%            | 1.07   [0.83, 1.39] |
| Lin 2006          | 53 108 116         | 33.6%            | 0.69   [0.55, 0.86] |
| ProCESS 2014      | 128 415 412        | 35.8%            | 0.91   [0.75, 1.11] |

Total (95% CI) 572 582 100.0% 0.87 [0.68, 1.11]

Total events 216 258

Heterogeneity: Tau² = 0.03; Chi² = 7.06, df = 2 (P = 0.03); I² = 72%
Test for overall effect: Z = 1.10 (P = 0.27)

4. Standard EGDT vs. Early lactate clearance

| Study or Subgroup | Standard EGDT Total | Early lactate clearance Total | Weight | Risk Ratio M-H | Random 95% CI | Risk Ratio M-H | Random 95% CI |
|-------------------|---------------------|-----------------------------|--------|----------------|---------------|----------------|---------------|
| Jones 2010        | 34 150 150         | 69.9%                       | 1.36   [0.86, 2.16] |
| Wang 2014         | 17 31 7           | 28.1%                       | 2.04   [1.00, 4.14] |
| Yu 2013           | 7 25 5            | 13.0%                       | 1.40   [0.51, 3.82] |

Total (95% CI) 206 201 100.0% 1.52 [1.06, 2.18]

Total events 58 37

Heterogeneity: Tau² = 0.00; Chi² = 0.80, df = 2 (P = 0.64); I² = 0%
Test for overall effect: Z = 2.25 (P = 0.02)

Figure 3 Forest plot for overall mortality. The analysis was stratified by study design. Risk ratio (RR) < 1.0 favors EGDT. Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel.
28d Mortality

| Study or Subgroup   | EGDT Events | Control Events | Total Events | Weight | Risk Ratio M-H | Random | 95% CI       | Risk Ratio M-H | Random | 95% CI       |
|---------------------|-------------|----------------|--------------|--------|----------------|---------|--------------|----------------|---------|--------------|
| Andrews 2014        | 35          | 49             | 84           |        | 1.07 [0.83, 1.39]|         |              |                 |         |              |
| ARISE 2014          | 117         | 792            | 909          |        | 0.93 [0.74, 1.17]|         |              |                 |         |              |
| Group 2010          | 39          | 157            | 196          |        | 0.58 [0.42, 0.81]|         |              |                 |         |              |
| Rivers 2001         | 40          | 130            | 170          |        | 0.67 [0.49, 0.92]|         |              |                 |         |              |
| Wang 2014           | 17          | 31             | 48           |        | 2.04 [1.00, 4.14]|         |              |                 |         |              |
| Yu 2013             | 7           | 25             | 32           |        | 1.40 [0.51, 3.82]|         |              |                 |         |              |

Total (95% CI) 1184 1181 100.0% 0.91 [0.69, 1.20]

Total events 255 298

Heterogeneity: Tau² = 0.08; Chi² = 17.37, df = 5 (P = 0.004); I² = 71%

Test for overall effect: Z = 0.67 (P = 0.50)

In-hospital Mortality

| Study or Subgroup   | EGDT Events | Control Events | Total Events | Weight | Risk Ratio M-H | Random | 95% CI       | Risk Ratio M-H | Random | 95% CI       |
|---------------------|-------------|----------------|--------------|--------|----------------|---------|--------------|----------------|---------|--------------|
| Andrews 2014        | 34          | 53             | 87           |        | 1.06 [0.79, 1.41]|         |              |                 |         |              |
| ARISE 2014          | 115         | 793            | 908          |        | 0.92 [0.73, 1.17]|         |              |                 |         |              |
| Jones 2010          | 34          | 150            | 184          |        | 1.36 [0.68, 2.16]|         |              |                 |         |              |
| Lin 2006            | 58          | 106            | 164          |        | 0.75 [0.61, 0.93]|         |              |                 |         |              |
| ProCESS 2014        | 173         | 885            | 1058         |        | 1.04 [0.82, 1.31]|         |              |                 |         |              |
| Rivers 2001         | 38          | 130            | 168          |        | 0.68 [0.47, 0.91]|         |              |                 |         |              |

Total (95% CI) 2119 1708 100.0% 0.91 [0.77, 1.09]

Total events 452 412

Heterogeneity: Tau² = 0.03; Chi² = 12.23, df = 5 (P = 0.03); I² = 59%

Test for overall effect: Z = 1.00 (P = 0.32)

Figure 4 Forest plot for 28-d mortality and in-hospital mortality. The analysis was stratified by study design. Risk ratio (RR) < 1.0 favors EGDT.

Abbreviations: CI, confidence interval; M-H, Mantel-Haenszel.

Table 3 Pooled analysis of secondary outcomes

| Outcome                      | Comparison                              | Number of studies | MD or RR (95% CI) | P       | I² (%) |
|------------------------------|-----------------------------------------|-------------------|-------------------|---------|--------|
| Length of ICU stay (d)       | EGDT versus control group               | 6                 | -0.20 (-1.31 to 0.92) | 0.73    | 75     |
| Length of in-hospital stay (d)| EGDT versus control group               | 4                 | 0.42 (-1.02 to 1.86) | 0.57    | 12     |
| Mechanical ventilation rate  | EGDT versus control group               | 5                 | 0.96 (0.85 to 1.09)  | 0.53    | 43     |
| Mechanical ventilation days  | EGDT versus control group               | 4                 | -0.91 (-2.34 to 0.52) | 0.21    | 95     |
| Vasopressor support rate     | EGDT versus control group               | 6                 | 1.03 (0.93 to 1.15)  | 0.58    | 69     |
| Inotropic agents support     | EGDT versus control group               | 5                 | 2.23 (1.06 to 4.67)  | 0.03    | 84     |
|                              | EGDT versus usual care group            | 4                 | 2.37 (1.02 to 5.51)  | 0.05    |        |
|                              | EGDT versus early lactate clearance     | 1                 | 1.60 (0.54 to 4.78)  | 0.40    | 88     |
| Fluid administration in first 6 h (L) | EGDT versus control group | 7 | 0.88 (-0.17 to 1.93) | 0.10    | 99     |
|                              | EGDT versus usual care group            | 5                 | 1.24 (0 to 2.48)     | 0.05    | 99     |
|                              | EGDT versus early lactate clearance     | 2                 | 0.02 (-0.46 to 0.49) | 0.27    | 17     |
| Red cell transfusion rate in first 6 h | EGDT versus control group | 5 | 1.76 (1.11 to 2.78) | 0.04    | 76     |
|                              | EGDT versus usual care group            | 3                 | 2.26 (1.54 to 3.31)  | <0.01   | 71     |
|                              | EGDT versus early lactate clearance     | 2                 | 0.72 (0.27 to 1.94)  | 0.52    | 37     |

Abbreviations: EGDT early goal-directed therapy, MD mean difference, RR relative risk.
A total of 5 studies including 3,097 patients reported data on red cell transfusion rate in the first 6 h with considerable heterogeneity ($\chi^2 = 16.49, I^2 = 76\%$). EGDT was associated with a higher red cell transfusion rate in comparison to the control group (RR 1.76, 95% CI: 1.11 to 2.78; $P = 0.04$). There was also a significant difference between EGDT and the usual care group (RR 2.26, 95% CI: 1.54 to 3.31; $P < 0.01$). No significant difference was found between the EGDT group and the early lactate clearance group ($P = 0.52$).

**Publication Bias**

No evidence of publication bias was detected for RR of mortality by either funnel plots or Egger's test ($t = 1.37; P = 0.209$) (Figure 5).

**Sensitivity analysis**

In order to assess the stability of the results of the current meta-analysis, we performed a sensitivity analysis for each outcome by removing a study. Statistically similar results were obtained after omitting each of the studies (Table 4), indicating a moderate degree of stability in the findings of this systematic review.

**Discussion**

**Key findings**

We performed a systematic review of the literature and identified 10 RCTs reporting data on EGDT versus control group among more than 3,700 patients with severe or septic shock. We found that patients receiving EGDT had a similar risk of mortality compared with those in the control group. In a subgroup analysis, a difference in favor of standard EGDT was seen in comparison to the usual care group. However, EGDT was associated with a higher rate of mortality compared with the early lactate clearance group. In a first 6 h-protocol of EGDT, compared with usual care, patients in EGDT received more inotropic agents support, fluid administration, and blood transfusion. No significant differences were found in length of ICU stay or in-hospital stay, ventilation rate, ventilation days, and vasopressor support between EGDT and the control group.

**Comparison with previous studies**

As shown in Table 5, there were a few meta-analysis studies to evaluate the effect of EGDT or a 6-h sepsis bundle including EGDT on patients with severe sepsis or septic shock [12,26-28]. All four previous meta-analyses showed that EGDT was associated with a survival benefit. However, there were some problems with these meta-analyses. Among them, the latest meta-analysis [28], included 13 RCTs, but only 7 studies in the EGDT subgroup; second, some protocols which differed from the original one and that recommended by the surviving sepsis campaign guidelines were included [29-32]; third, two inappropriate RCTs were included: one was not an RCT but a before-and-after study, and the other included non-sepsis patients with no information about mortality of sepsis subgroup; fourth, studies about EGDT comparing it with early lactate clearance were not included [20,22,24]; fifth, the latest ARISE study [13] was not included.

In the other three previous meta-analyses, the recent trials were not included. The positive findings largely

**Table 4 Sensitivity analysis for mortality by omitting each study in random-effects model**

| Study omitted | RR (95% CI)       | P value |
|---------------|-------------------|---------|
| Andrews [21]  | 0.89 (0.75 to 1.06)| 0.19    |
| ARISE [13]    | 0.90 (0.75 to 1.08)| 0.27    |
| Jing [8]      | 0.94 (0.80 to 1.12)| 0.50    |
| Jones [22]    | 0.88 (0.75 to 1.03)| 0.11    |
| Lin [23]      | 0.95 (0.80 to 1.11)| 0.50    |
| ProCESS [14]  | 0.91 (0.75 to 1.11)| 0.37    |
| Rivers [4]    | 0.94 (0.79 to 1.12)| 0.47    |
| Wang [20]     | 0.92 (0.78 to 1.08)| 0.31    |
| Wang [20]     | 0.87 (0.76 to 1.01)| 0.07    |
| Yu [24]       | 0.90 (0.76 to 1.06)| 0.20    |

![Figure 5] Assessment of publication bias. (A) Funnel plot. (B) Egger's test. Abbreviations: SE, standard error, RR, risk ratio.
relied on data from observational studies, so potential selection and allocation bias acted as major confounders. Second, some inappropriate studies which evaluated compliance with EGDT or 6-h sepsis bundles were included [33,34]. Third, mortality rates of severe sepsis or septic shock have dropped year by year over time [35,36]. However, all the included observational studies used a before-and-after design, and the patients in the EGDT group were treated 1 to 2 years later than those in the control group, introducing a time bias.

In contrast, the present systematic review includes data from 10 RCTs with more than 3,700 patients with severe sepsis and septic shock. Such studies might be more likely to accurately represent the efficacy of EGDT on patients with severe sepsis and septic shock. An ongoing multicenter RCT (ProMISe, ISRCTN36307479) [37] in the United Kingdom comparing EGDT with usual care for severe sepsis or septic shock will provide us more information in the future.

Clinical implications and future studies
Among the RCTs included in the present systematic review, five recent studies (after 2013) [13,14,20,21,24] showed no survival benefit with EGDT for patients with severe sepsis and septic shock, which indicates that the efficacy of EGDT should be reevaluated. Compared with usual care, continuous monitoring of ScvO\(_2\), which requires invasive central venous catheterization and special equipment, is the key method of EGDT. However, its effectiveness is still uncertain [38]. In contrast, it is convenient to monitor lactate levels, and early lactate clearance may be more effective for severe sepsis or septic shock than EGDT in the present meta-analysis. A recent multicenter RCT [39] also reported that early lactate-guided therapy significantly reduced hospital mortality in critically ill patients with hyperlactatemia; however, it was not included in the meta-analysis because non-sepsis patients were enrolled in the study. Thus, future studies should focus on comparing EGDT with early lactate clearance as a therapeutic option in severe sepsis or septic shock.

Strengths and limitations
To the best of our knowledge, this study is the first to systematically evaluate the effect of EGDT on patients with severe sepsis or septic shock based on RCTs. Our search strategy was broad and included studies in both English and Chinese. It included data from more than 3,700 patients, 10 RCTs, and 6 countries, from different regions of Asia, North America, Oceania, and Africa. Two independent investigators also rigorously assessed methodological quality.

However, our study also has several limitations. First, although 10 studies were included in this systematic review, three of the included studies were small (less than 60 patients). There was moderate evidence for heterogeneity in main outcomes such as mortality. Subgroup analysis was performed to solve this when data were available, but subgroup analysis in a meta-analytical study can only provide weak hypothesis-generating evidence. Thus, we do not believe that these results constitute a reason to change clinical practice but rather support the need for further research.

Second, because of the nature of the intervention and logistic problem, the studies were not double-blinded. Although it might not influence the primary outcome (mortality), there is still potential for bias.

Third, although we extracted data on mortality at the end of follow-up, the duration of each study varied from 14 days in one study [25], to 28 days in 3 studies [8,20,24], to in-hospital mortality in 6 studies [4,13,14,21-23]. Even so, although the end points of different follow-up periods could modify the absolute risk, they should not bias the overall RR.

Fourth, the variation in baseline among studies might also be a contributing factor to clinical and possibly statistical heterogeneity. For instance, the APACHE II score and total mortality in the ARISE study and River’s study were 15, 18.7% and 20, 45.6%, respectively. In addition, the intervention in the control group (usual care group) was not clear and might be different among studies.

Last but not least, only published studies with selective databases were included for data analysis. The unavailability

### Table 5 Comparison of our study with previous meta-analyses

|                         | Our study | Gu [28] | Wira [26] | Chamberlain [27] | Barochia [12] |
|-------------------------|-----------|---------|-----------|------------------|---------------|
| Year of publication     | 2014      | 2014    | 2011      | 2010             | 2010          |
| Years of searching      | 1966-2014 | NA-2014 | 1980-2011 | 2004-2010        | 1980-2008     |
| Key finding             | EGDT      | GDT     | EGDT      | 6-h sepsis bundle| 6 h sepsis bundle|
| Studies included        | 10        | 13      | 25        | 11               | 8             |
| Observational studies   | 0         | 0       | 14        | 11               | 7             |
| Abstracts               | 0         | 0       | 10        | 0                | 0             |
| Survival benefit        | Negative  | Favors GDT| Favors EGDT| Favors EGDT      | Favors EGDT   |

**Abbreviations:** EGDT early goal-directed therapy, GDT goal-directed therapy.
of unreported outcomes possibly could result in reporting bias. Regardless of these limitations, we have minimized bias throughout the process by our methods of study identification, data selection, and statistical analysis, as well as in our control of publication bias and sensitivity. These steps should strengthen the stability and accuracy of the meta-analysis.

Conclusions
Available RCTs do not show a significant difference in mortality between the EGDT group and the control group. In subgroup analysis, EGDT is associated with a lower mortality rate in comparison to the usual care group. However, EGDT was associated with a higher mortality rate in comparison to the early lactate clearance group. Further high-quality RCTs comparing EGDT and early lactate clearance are desirable.

Appendix 1: Electronic search strategies

1) Medline
   1. sepsis.ti,ab,kw.
   2. septic shock.ti,ab,kw.
   3. sepsis/
   4. 1 or 2 or 3
   5. EGDT.ti,ab,kw.
   6. goal directed.ti,ab,kw.
   7. goal oriented.ti,ab,kw.
   8. bundle.ti,ab,kw.
   9. hemodynamic optimization.ti,ab,kw.
   10. Resuscitation.ti.
   11. protocol.ti.
   12. program.ti.
   13. procedure.ti.
   14.5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13
   15.4 and 13
   16. random.ti,ab,kw.
   17. randomly.ti,ab,kw.
   18. randomized.ti,ab,kw.
   19.16 or 17 or 18
   20.15 and 19
   21. limit 20 to humans

2) Embase
   1. sepsis.ti,ab,kw.
   2. septic shock.ti,ab,kw.
   3. sepsis/
   4. 1 or 2 or 3
   5. EGDT.ti,ab,kw.
   6. goal directed.ti,ab,kw.
   7. goal oriented.ti,ab,kw.
   8. bundle.ti,ab,kw.
   9. hemodynamic optimization.ti,ab,kw.
   10. Resuscitation.ti.
   11. program.ti.
   12. procedure.ti.

3) Cochrane Library
   1. sepsis.ti,ab,kw.
   2. septic shock.ti,ab,kw.
   3. 1 or 2
   4. EGDT.ti,ab,kw.
   5. goal directed.ti,ab,kw.
   6. goal oriented.ti,ab,kw.
   7. bundle.ti,ab,kw.
   8. hemodynamic optimization.ti,ab,kw.
   9. Resuscitation.ti.
   10. protocol.ti.
   11. program.ti.
   12. procedure.ti.
   13.4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12
   14.3 and 13
   15. random.ti,ab,kw.
   16. randomly.ti,ab,kw.
   17. randomized.ti,ab,kw.
   18.15 or 16 or 17
   19.14 and 18

Abbreviations
APACHE: Acute Physiology and Chronic Health Evaluation; CVP: central venous pressure; EGDT: early goal-directed therapy; Hb: hemoglobin; JVP: jugular venous pressure; MAP: mean arterial pressure; MD: mean difference; RCT: randomized controlled trial; RR: relative risk; SAPS: Simplified Acute Physiology Score; SBP: systolic blood pressure; ScvO2: central venous oxygen saturation; UO: urine output.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
PF, as the corresponding author of this paper, was mainly responsible for the program design and modification. LZ wrote the first draft. LZ and GZ assessed each trial independently and recorded eligibility, quality, and outcomes. PF provided arbitration in case of disagreement. LH and GZ searched for relevant studies. All authors read and approved the final manuscript.

Author details
1Division of Nephrology and Intensive Care Medicine, West China Hospital of Sichuan University, Chengdu, Sichuan, China. 2Division of Intensive Care Unit, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. 3Division of Intensive Care Unit, West China Hospital of Sichuan University, Chengdu, Sichuan, China. 4Division of Nephrology, West China Hospital of Sichuan University, Chengdu, Sichuan, China.

Received: 14 November 2014 Accepted: 6 March 2015
Published online: 03 April 2015
References

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29:1303–10.

2. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med. 2007;35:1244–50.

3. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med. 2003;348:1546–54.

4. Rivers E, Nguyen B, Havstad S, Resller J, Muzzin A, Knobloch B, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med. 2001;345:1368–77.

5. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32:858–73.

6. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock. 2008. Crit Care Med. 2008;36:296–327.

7. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock - 2012. Crit Care Med. 2013;41:580–637.

8. Jing Y. The effect of early goal-directed therapy on treatment of critical patients with severe sepsis/septic shock: a multi-center, prospective, randomized, controlled study. Zhongguo Wei Zhong Bing Jiu Yi Xue. 2010;22:331–4.

9. Micel ST, Roubianin N, Heurung T, Bode M, Williams J, Harrison C, et al. Before-after study of a standardized hospital order set for the management of septic shock. Crit Care Med. 2006;34:2707–13.

10. Shapiro NI, Howell MD, Talmor D, Lahey D, Ngo L, Buras J, et al. Implementation and outcomes of the Multiple Urgent Sepsis Therapies (MUST) protocol. Crit Care Med. 2006;34:1025–32.

11. Puskarich MA, Marchick MR, Kline JA, Steuerwald MT, Jones AE. A randomized trial of protocol-based care for early septic shock. Crit Care Med. 2008;354:637–43.

12. Barochia AV, Cui X, Vtiberg D, Suteddini AF, O'Grady NP, Banks SM, et al. Bundled care for septic shock: an analysis of clinical trials. Crit Care Med. 2013;41:568–78.

13. Arise Investigators. Goal-directed resuscitation for patients with early septic shock. N Engl J Med. 2014;371:496–506.

14. Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, Pike F, et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med. 2014;370:1683–93.

15. Kelm DJ, Penn JT, Cartin-Ceba R, Gajic O, Schenck L, Kennedy CC. Fluid and take full advantage of:

www.biomedcentral.com/submit

Immediate publication on acceptance
No space constraints or color figure charges
Thorough peer review
Convenient online submission
Inclusion in PubMed, CAS, Scopus and Google Scholar
Research which is freely available for redistribution